Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
K L WinthropS-H ParkA GulMario Humberto CardielJ J Gomez-ReinoY TanakaK KwokT LukicE MortensenD Ponce de LeonR RieseH ValdezPublished in: Annals of the rheumatic diseases (2015)
Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
Keyphrases
- mycobacterium tuberculosis
- rheumatoid arthritis
- ulcerative colitis
- pulmonary tuberculosis
- disease activity
- ankylosing spondylitis
- risk factors
- interstitial lung disease
- high throughput
- study protocol
- stem cells
- randomized controlled trial
- newly diagnosed
- emergency department
- hiv aids
- systemic lupus erythematosus
- mesenchymal stem cells
- single cell
- adverse drug
- hiv infected
- hepatitis c virus